In the GHM Controversial Issue Brief titled ‘How can we collaborate with Big Pharma in global health?‘, Nicolai Lohse writes:
The combination of pharmaceutical companies and global health invariably makes one think of the huge lack of access to medicine in low- and middle-income countries (LMIC). Drugs are either not affordable, not available at all, only available intermittently due to frequent pharmacy stock-outs, of poor quality, ineffective, or they are counterfeit and may even be unsafe.
Making quality medicine available, affordable, and accessible to all who need them is extremely complicated and requires a coordinated effort by many global health actors – including the pharmaceutical industry. In this need for collaborative solutions lies also the key to involving drug companies as a partner in global health.
Download the brief on Big Pharma.
Photo credit: Erling Høg